

# RNA Interference (RNAi): Market Research Report

<https://marketpublishers.com/r/R624E3CC117EN.html>

Date: March 2012

Pages: 792

Price: US\$ 4,800.00 (Single User License)

ID: R624E3CC117EN

## Abstracts

This report analyzes the worldwide markets for RNA Interference (RNAi) in US\$ Million by the following Application Areas: Drug Discovery and Target Validation, Reagents, and siRNA Synthesis.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World.

Annual estimates and forecasts are provided for the period 2009 through 2017.

Also, a six-year historic analysis is provided for these markets.

The report profiles 135 companies including many key and niche players such as Alnylam Pharmaceuticals, Inc., Benitec Limited, Bioneer Corp., Calando Pharmaceuticals, Inc., Cenix BioScience GmbH, Devgen NV, Dharmacon, Inc., Dicerna Pharmaceuticals, Inc., Exiqon A/S, Genesis Research & Development Corporation Limited, Halo-Bio RNAi Therapeutics, Inc., Marina Biotech, Inc., OPKO Health, Inc., Polyplus-transfection SA, Quark Pharmaceuticals, Inc., Galena Biopharma, Sigma-Aldrich Co., Silence Therapeutics, and Tekmira Pharmaceuticals Corp.

Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based upon search engine sources in the public domain.

## Contents

### **I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS**

Study Reliability and Reporting Limitations  
Disclaimers  
Data Interpretation & Reporting Level  
Quantitative Techniques & Analytics  
Product Definitions and Scope of Study  
Product Segments  
Drug Discovery and Target Validation  
Reagents  
SiRNA Synthesis

### **II. EXECUTIVE SUMMARY**

#### **1. INDUSTRY OUTLOOK**

RNA Interference: A Historic Perspective  
RNAi Time Line

#### **2. INDUSTRY OVERVIEW**

Leading Regional Markets  
High-throughput Screening: A Promising Application for RNA Interference  
Growth Drivers

#### **3. MARKET OUTLOOK**

RNA Interference: A Potential Oligonucleotide Technology  
A Review of Select Classes of Oligonucleotides Competing with siRNA  
Oligonucleotide Market Sustains Recession  
Select RNAi-based Therapeutics in the Pipeline  
RNAi: A Leading Research Tool in Gene-Silencing  
RNAi-based Drugs to Emerge as a New Class of Therapeutics  
RNAi-based Therapeutics to Drive the Growth of RNAi Market  
Statistics on Select Diseases  
Cancer

**Table 1.** Global Cancer Incidence by Region: 2009 (includes corresponding Graph/Chart)

**Table 2.** Global Cancer Incidence by Country: 2009 (includes corresponding Graph/Chart)

**Table 3.** Global Cancer Incidence by Income Group: 2009 (includes corresponding Graph/Chart)

**Table 4.** Global Cancer Related Deaths in Male Population by Site: 2007 (includes corresponding Graph/Chart)

**Table 5.** Global Cancer Related Deaths in Female Population by Site: 2007 (includes corresponding Graph/Chart)

Cardiovascular Diseases

**Table 6.** Global Coronary Heart Disease Prevalence by Region (includes corresponding Graph/Chart)

**Table 7.** Deaths Due to Major Cardiovascular Diseases in the US: Percentage Share Breakdown by Disease Type (includes corresponding Graph/Chart)

Huntington's Disease (HD)

Diabetic Retinopathy

**Table 8.** Diabetic Retinopathy Patient Prevalence in the US by Diabetes Type: 2006-2015 (In Thousand Patients) (includes corresponding Graph/Chart)

**Table 9.** Diabetic Retinopathy Patient Prevalence in the US by Age Group: 2006-2012 (includes corresponding Graph/Chart)

**Table 10.** Diabetic Retinopathy Prevalence in Type-1 Diabetic Patients in the US by Age Group: 2006-2012 (includes corresponding Graph/Chart)

RNAi in Drug Therapeutics

RNAi: Select Targeted Clinical Areas

Age Related Macular Degeneration: A Key Clinical Area of Focus

Select Promising RNAi Drugs in Pipeline: A Review

## **ALN-VSP**

Atu027

## **CALAA-01**

## **CEQ501**

RNAi Therapeutics: Challenges in a Nutshell

Drug Delivery: A Key Challenge Facing RNAi-based Therapeutics

Select Methods of Systemic Drug Delivery under Development

Select RNAi Drug Delivery Technologies under Development

Other Challenges Facing RNAi-based Therapeutics

A Snapshot of Select RNAi Delivery Platforms Under Development

Lipid Nanoparticle (LNP) siRNA Delivery Technology Platform (Tekmira)

RONDEL (Calando Pharmaceuticals)

Lipid and Polymer Based Delivery Platforms (Silence Therapeutics)

AtuPlex/AtuFect Delivery Platform

PolyTran™ Delivery Platform

RNAi Nanoplex Delivery Technology (Intradigm Corporation)

DiLA2 Platform (Marina Biotech)

## **4.PRODUCT OVERVIEW**

History of RNA Interference

Co-Suppression and Quelling

VIGS (Virus Induced Gene Suppression)

RNA Interference or Post Transcriptional Silencing

The RNAi Pathway

siRNA and miRNA

RISC Complex

Transfer and Heritance

The Difference

Other Short RNAs mediating RNA Interference

Small Hairpin RNA (shRNA)

Repeat associated small interfering RNA (rasiRNA)  
Comparison of Various Types of RNAs in RNA Interference

## **5.APPLICATIONS OF RNA INTERFERENCE**

Significance of RNA Interference  
Role of RNAi in Gene Silencing  
RNA Interference Affects Protein Synthesis at the Level of Translation  
Role of mRNA in Gene Expression  
RNAi: Application Areas  
RNAi in Drug Discovery and Target Validation  
RNAi in Functional Genomics  
Why RNAi over Other Techniques?  
Use of RNAi in the Study of Functional Genomics in Humans  
Model Organisms and Off-target Effects  
Select Target Validation Systems  
RNAiMonitor™ (Clontech Laboratories, Inc)  
GenoExplorer™ microRNA System (GenoSensor Corp)  
RNAi Reagents  
Select RNAi Reagents and Transfection Kits  
Lipofectamine™ RNAiMAX Transfection Reagent (Life Technologies/Invitrogen)  
siGENOME® siRNA Reagents (Dharmacon RNA Technologies)  
ON-TARGETplus™ SMARTpool Reagents (Dharmacon RNA Technologies)  
Vector-based RNAi Reagents (Thermo Scientific)  
siRNA transfection kits (Bio-Rad Lab)  
Fluorescent Reagents (OZ Biosciences)  
ICAFectin™ 442 siRNA Transfection Reagent (Tekmira)  
TransIT®-mRNA Transfection Kit (Mirus Bio llc)  
siRNA Synthesis  
siRNA: A Popular Tool for the Detection and Induction of Gene Silencing  
Methods of siRNA Synthesis  
Select Synthetic siRNAs  
Synthetic siRNAs (Eurogentec SA)  
Ambion® In Vivo Pre-designed siRNAs (Life Technologies)  
Silencer® Pre-Designed & Validated siRNAs (Life Technologies)  
HuSH-29: pre-designed shRNA (OriGene Technologies, Inc.)  
A Review of other Application Areas of RNAi  
RNAi in Agriculture and Plant Biotechnology  
miRNA as Biomarkers and Therapeutic Targets – An Insight

miRNA: Clinical Areas under Focus

## **6.REGULATORY APPROVALS**

Asuragen Obtains Notices of Allowance for Several miRNA Patent Applications

Genable Technologies Obtains Orphan Designation by EMA

Benitec Obtains RNA Interference Patent from EPO

Silence Therapeutics Bags New Patent Rights

Benitec Receives RNAi Related Patent Grant from USPTO

Marina Obtains Notices of Allowance for siRNA Patent Applications

USPTO Grants a RNAi Related Patent to Benitec

Alnylam Receives Patent Rights for Woppmann Patent Series

Kylin Bags Patent Rights for pRNAi Technology

Allele Biotechnology Obtains Patent Approval for DNA-Encoded RNAi

Silence Therapeutics Obtains Notices of Allowance for RNAi Patent Applications

RXi Obtains Notices of Allowance for siRNA Patent Applications

Intradigm Obtains Patent for siRNA Sequence

Intradigm Receives Key RNAi Patent Allowance

## **7.TECHNOLOGICAL INNOVATIONS**

Exiqon Launches miRCURY LNA™ miRNA Family Inhibitors

Cellecta Introduces New Open Source Genome-Wide RNAi Screening Platform

Tekmira, Alnylam, and UBC Co-Develop New Lipid Component

ID Tech Introduces Improved miRCat™ Small RNA Cloning System

Integrated DNA Technologies Launches Transductin™

Abnova Unveils New Gene Silencing Tool

Polyplus-transfection Introduces jetPRIME™ Transfection Reagent

Sigma-Aldrich Launches Gene-Specific MISSION esiRNA

CombiMatrix to Introduce miRNA Cancer-Screening Test in the US

GeneCopoeia Unveils microRNA Tools and Reagents for Functional Analysis

Invitrogen Introduces Invivofectamine™ Delivery Reagent

## **8.RECENT INDUSTRY ACTIVITY**

RXi Pharmaceuticals Corp. is Now Galena Biopharma

Genix to Establish New Subsidiary

Arrowhead Acquires Stake in US Subsidiary, Calando

RXi and Generex Obtain Positive Research Data for Exploring RNAi Technology

Rosetta Obtains Permit for miRNA-based Diagnostics in NY  
Alnylam Pharmaceuticals Introduces Alnylam 5x15 Product Strategy  
Cenix BioScience Receives R&D Grant from Saxony  
Kyowa and Dicerna Expand Research Collaboration  
MDRNA Acquires BNA Intellectual Property from Valeant  
Sirnaomics Partners with a Chinese Company for RNAi Therapeutics Development  
Kylin Obtains IRS Grant for Advancing Research on pRNAi Nanoparticle  
Tekmira Obtains New License for Alnylam's InterfeRx™  
RXi to Collaborate with EyeGate  
Sigma Life Partners with SwitchGear Genomics for miRNA Validation System  
Marina Biotech Acquires Novosom's SMARTICLES® Intellectual Property Estate  
Quark to Collaborate with Nitto Denko for Co-Developing siRNA-based Anti-fibrotic Drug  
AstraZeneca and Silence Therapeutics Extend R&D Alliance  
Silence Therapeutics and AstraZeneca Extend siRNA Delivery Partnership  
MDRNA to Take Over Cequent  
Traversa and sanofi-aventis Ink Research Agreement  
Pfizer to Develop HCV Compounds of Tacere Therapeutics  
Intradigm and Silence Therapeutics Merge  
Sirna Therapeutics and Allergan form Joint Drug Development Alliance  
Benitec Collaborates with CCIA  
RXi Pharmaceuticals Obtains Advirna's RNAi Technology  
RXi Obtains Exclusive Licensing Rights to Advirna's Delivery Technologies  
Dicerna Collaborates with Archemix  
Alnylam Collaborates with GSK to Donate Several RNAi Technology Patents  
AstraZeneca and Cenix Extend Research Agreement on RNA Interference  
Allergan Stops Development of AGN-745 Treatment  
Tekmira Inks Agreement with Roche  
MDRNA Inks Licensing Agreement with Novartis  
MDRNA Inks Agreement with Roche for Developing RNAi Therapeutics  
Mirna Therapeutics to Investigate Therapeutic Potential of miRNA  
Cenix and Boehringer Ingelheim Ink Research Agreement  
Mirna and M. D. Anderson to Explore miRNA Therapeutics in Prostate Cancer  
Cubist Partners with Alnylam Pharmaceuticals  
Liquidia to License Certain Rights of PRINT technology to Abbott

## **9. STRATEGIC CORPORATE DEVELOPMENTS – A HISTORIC PERSPECTIVE BUILDER**

Invitrogen Merges with Applied Biosystems  
MDRMA Obtains Rights to RiboTask's UNA Technology  
Roche Takes Over Mirus  
Thermo Fischer Snaps Up Open Biosystems  
Protiva and Tekmira Complete the Merger of Business Operations  
Takeda and Alnylam Enter into Strategic Alliance  
SR Pharma Plc. is Now Silence Therapeutics Plc.

## 10.FOCUS ON SELECT GLOBAL PLAYERS

Alnylam Pharmaceuticals, Inc. (USA)  
Benitec Limited (Australia)  
Bioneer Corp. (Korea)  
Calando Pharmaceuticals, Inc. (USA)  
Cenix BioScience GmbH (Germany)  
Devgen NV (Belgium)  
Dharmacon, Inc. (USA)  
Dicerna Pharmaceuticals, Inc. (USA)  
Exiqon A/S (Denmark)  
Genesis Research & Development Corporation Limited (New Zealand)  
Halo-Bio RNAi Therapeutics, Inc. (USA)  
Marina Biotech, Inc. (USA)  
OPKO Health, Inc. (USA)  
Polyplus-transfection SA (France)  
Quark Pharmaceuticals, Inc. (USA)  
Galena Biopharma (USA)  
Sigma-Aldrich Co. (USA)  
Silence Therapeutics (UK)  
Tekmira Pharmaceuticals Corp. (Canada)

## 11.GLOBAL MARKET PERSPECTIVE

**Table 11.** World Recent Past, Current & Future Analysis for RNA Interference by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 12.** World Historic Review for RNA Interference by Geographic Region – US,



Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 13.** World 15-Year Perspective for RNA Interference by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

**Table 14.** World Recent Past, Current & Future Analysis for RNA Interference in Drug Discovery and Target Validation Applications by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 15.** World Historic Review for RNA Interference in Drug Discovery and Target Validation Applications by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 16.** World 15-Year Perspective for RNA Interference in Drug Discovery and Target Validation Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

**Table 17.** World Recent Past, Current & Future Analysis for RNA Interference Reagents by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 18.** World Historic Review for RNA Interference Reagents by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 19.** World 15-Year Perspective for RNA Interference Reagents by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

**Table 20.** World Recent Past, Current & Future Analysis for siRNA Synthesis by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)

**Table 21.** World Historic Review for siRNA Synthesis by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 22.** World 15-Year Perspective for siRNA Synthesis by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

### III. MARKET

#### 1.THE UNITED STATES

##### A. Market Analysis

Outlook

Technological Innovations

Strategic Corporate Developments

Focus on Select Major Players

##### B. Market Analytics

**Table 23.** The US Recent Past, Current & Future Analysis for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 24.** The US Historic Review for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 25.** The US 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017(includes corresponding

Graph/Chart)

## 2.CANADA

- A. Market Analysis
  - Strategic Corporate Development
  - Focus on Select Major Player
- B. Market Analytics

**Table 26.** Canadian Recent Past, Current & Future Analysis for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 27.** Canadian Historic Review for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 28.** Canadian 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017(includes corresponding Graph/Chart)

## 3.JAPAN

- A. Market Analysis
  - Strategic Corporate Developments
- B. Market Analytics

**Table 29.** Japanese Recent Past, Current & Future Analysis for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 30.** Japanese Historic Review for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently

Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008  
(includes corresponding Graph/Chart)

**Table 31.** Japanese 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

## 4.EUROPE

### Market Analytics

**Table 32.** European Recent Past, Current & Future Analysis for RNA Interference Market by Geographic Region – France, Germany, Italy, UK, and Rest of European Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 33.** European Historic Review for RNA Interference by Geographic Region – France, Germany, Italy, UK, and Rest of European Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 34.** European 15-Year Perspective for RNA Interference by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, and Rest of European for Years 2003, 2011 & 2017(includes corresponding Graph/Chart)

**Table 35.** European Recent Past, Current & Future Analysis for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 36.** European Historic Review for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 37.** European 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation,

Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

#### **4A.FRANCE**

A. Market Analysis

Technological Innovation

Strategic Corporate Development

Focus on Select Major Player

B. Market Analytics

**Table 38.** French Recent Past, Current & Future Analysis for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 39.** French Historic Review for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 40.** French 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

#### **4B.GERMANY**

A. Market Analysis

Strategic Corporate Developments

B. Market Analytics

**Table 41.** German Recent Past, Current & Future Analysis for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)

**Table 42.** German Historic Review for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 43.** German 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

#### **4C.ITALY**

##### Market Analytics

**Table 44.** Italian Recent Past, Current & Future Analysis for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 45.** Italian Historic Review for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 46.** Italian 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017(includes corresponding Graph/Chart)

#### **4D.THE UNITED KINGDOM**

##### A. Market Analysis

Technological Innovations

Focus on Select Major Player

##### B. Market Analytics

**Table 47.** The UK Recent Past, Current & Future Analysis for RNA Interference Market

by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 48.** The UK Historic Review for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 49.** The UK 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

#### **4E.REST OF EUROPE**

##### A. Market Analysis

Strategic Corporate Developments

Focus on Select Major Players

##### B. Market Analytics

**Table 50.** Rest of European Recent Past, Current & Future Analysis for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 51.** Rest of European Historic Review for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 52.** Rest of European 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017(includes corresponding Graph/Chart)

#### **5.ASIA-PACIFIC**

- A. Market Analysis
  - Strategic Corporate Developments
  - Focus on Select Major Players
- B. Market Analytics

**Table 53.** Asia-Pacific Recent Past, Current & Future Analysis for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 54.** Asia-Pacific Historic Review for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 55.** Asia-Pacific 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

## 6.REST OF WORLD

### Market Analytics

**Table 56.** Rest of World Recent Past, Current & Future Analysis for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 57.** Rest of World Historic Review for RNA Interference Market by Application Area – Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 58.** Rest of World 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017



(includes corresponding Graph/Chart)

#### **IV. COMPETITIVE LANDSCAPE**

Total Companies Profiled: 135 (including Divisions/Subsidiaries - 139)

Region/CountryPlayers

The United States

Canada

Japan

Europe

France

Germany

The United Kingdom

Spain

Rest of Europe

Asia-Pacific (Excluding Japan)

Africa

Middle East

## I would like to order

Product name: RNA Interference (RNAi): Market Research Report

Product link: <https://marketpublishers.com/r/R624E3CC117EN.html>

Price: US\$ 4,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R624E3CC117EN.html>